Suppression of immune response via inhibition of cathepsin S
AssigneeThe Brigham and Women's Hospital, Inc.
InventorsHidde L. Ploegh, Harold A. Chapman, Richard J. Riese, Paula R. Bryant, Matthew S. Bogyo
Life of this patent
Estimating the term…
Loading patent…
AssigneeThe Brigham and Women's Hospital, Inc.
InventorsHidde L. Ploegh, Harold A. Chapman, Richard J. Riese, Paula R. Bryant, Matthew S. Bogyo
Estimating the term…
Methods and products for suppressing a class II MHC-restricted immune response in a mammal, or in mammalian cells, are described. The methods depend upon inhibiting invariant chain proteolysis by cathepsin S from class II MHC/invariant chain complexes, thereby reducing the competency of Class II MHC molecules for binding antigenic peptides, reducing presentation of antigenic peptides by class II MHC molecules, and suppressing immune responses. The methods may be employed in the treatment of autoimmune diseases, allergic responses, and organ or tissue graft rejection. Pharmaceutical and therapeutic compositions which are peptide-based inhibitors of cathepsin S are also described.
An inhibitor of cathepsin S comprising
An inhibitor of cathepsin S comprising a peptide-based inhibitor of cathepsin S, wherein said peptide-based inhibitor of cathepsin S is based upon a peptide sequence which comprises at least about 2-20 consecutive residues from a preferred invariant chain cleavage site of cathepsin S, and wherein said peptide sequence is selected from the group consisting of Asn-Leu, Glu-Asn-Leu, Arg-Met, Leu-Arg-Met, Leu-Leu-Leu, and Leu-Hph.
Dependencies are inferred from the claim text.